MAM
CCCC icon

Martingale Asset Management’s C4 Therapeutics CCCC Stock Holding History

Martingale Asset Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-39,420
Closed -$124K – 812
2023
Q1 		$124K Buy
39,420
+6,724
+21% +$39.6K ﹤0.01% 800
2022
Q4 		$193K Buy
32,696
+1,500
+5% +$12.4K ﹤0.01% 796
2022
Q3 		$274K Buy
31,196
+1,767
+6% +$18.3K 0.01% 725
2022
Q2 		$222K Buy
+29,429
New +$259K ﹤0.01% 793
2022
Q1 		– Sell
-16,109
Closed -$519K – 813
2021
Q4 		$519K Buy
+16,109
New +$637K 0.01% 637

Other funds holding CCCC

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Martingale Asset Management's CCCC Position: Q2 2023 in Review

Martingale Asset Management sold out of C4 Therapeutics (CCCC) in Q2 2023, closing a stake of 39,420 shares — an estimated $124K sold.

Martingale Asset Management first reported a position in CCCC in Q4 2021 and held it in 5 quarters. The position peaked at $519K in Q4 2021. 100 funds tracked by Wall St. Rank hold CCCC as of Q2 2023.

  • Martingale Asset Management reported no remaining C4 Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Martingale Asset Management sold 39,420 C4 Therapeutics shares in Q2 2023, an estimated $124K.
  • Martingale Asset Management first reported a position in C4 Therapeutics in Q4 2021 and held it in 5 quarters.
  • Martingale Asset Management's C4 Therapeutics position peaked at $519K in Q4 2021.
  • 100 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2023.

Based on Martingale Asset Management's 13F filing for Q2 2023, filed 11 Aug 2023.